Loading...
Key Takeaway: Ribociclib plus fulvestrant maintained Health-Related Quality of Life (HRQOL) while improving progression-free survival compared to placebo. Hazard Ratios for deterioration favored Ribociclib but were not statistically significant.
Study Design & Arms
Baseline Quality of Life & Pain Scores
Comparison of baseline scores (Mean ± SD) between arms. Higher QOL is better; Lower Pain is better.
Hazard Ratios for Deterioration
Time to Definitive Deterioration (TTD) ≥10%. HR < 1 favors Ribociclib. Error bars represent 95% CI.
Global Health Status (QOL) Detail
Baseline scores were comparable. The Hazard Ratio (0.81) suggests a trend towards delayed deterioration with Ribociclib.
Pain Score Detail
Baseline pain was low in both groups. HR (0.77) for pain deterioration favored Ribociclib.
Effect Direction Summary
Summary of whether the intervention favored Ribociclib (Left) or Placebo (Right) based on Hazard Ratios.
Appendix: Raw Data & Sources
Extracted Metrics
| ID | Metric | Group | Value | Source |
|---|